A Dengue Vaccine

Research output: Contribution to journalShort surveypeer-review

Abstract

Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.

Original languageEnglish (US)
Pages (from-to)1
Number of pages1
JournalCell
Volume166
Issue number1
DOIs
StatePublished - 2016

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'A Dengue Vaccine'. Together they form a unique fingerprint.

Cite this